These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30061795)

  • 1. Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina - Budget Impact Analysis of Pregabalin.
    Catic T; Jusufovic R; Tabakovic V
    Mater Sociomed; 2018 Jun; 30(2):89-94. PubMed ID: 30061795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018.
    Catic T; Lekic L; Zah V; Tabakovic V
    Mater Sociomed; 2017 Sep; 29(3):176-181. PubMed ID: 29109662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
    Cooper TE; Wiffen PJ; Heathcote LC; Clinch J; Howard R; Krane E; Lord SM; Sethna N; Schechter N; Wood C
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012536. PubMed ID: 28779491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
    Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
    BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
    Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
    Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China.
    Wang BC; Liu D; Furnback WE; Bifa F; Dong P; Xie L; Guzauskas GF; Zhang S
    Pain Ther; 2016 Jun; 5(1):81-91. PubMed ID: 26932262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
    Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
    Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a prior authorization for pregabalin on health plan drug expenditures.
    Bazalo G; Weiss RC; Joshi AV
    Am J Manag Care; 2010 May; 16(5 Suppl):S154-9. PubMed ID: 20586524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.
    Darbà J; Kaskens L; Pérez C; Álvarez E; Navarro-Artieda R; Sicras-Mainar A
    Adv Ther; 2014 Jan; 31(1):1-29. PubMed ID: 24390901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination pharmacotherapy for the treatment of neuropathic pain in adults.
    Chaparro LE; Wiffen PJ; Moore RA; Gilron I
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD008943. PubMed ID: 22786518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review.
    Kaul I; Amin A; Rosenberg M; Rosenberg L; Meyer WJ
    Burns; 2018 Mar; 44(2):414-422. PubMed ID: 28822592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of pharmacoeconomic studies for pregabalin.
    Parker L; Huelin R; Khankhel Z; Wasiak R; Mould J
    Pain Pract; 2015 Jan; 15(1):82-94. PubMed ID: 24815038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
    Ritchie M; Liedgens H; Nuijten M
    Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of treating peripheral neuropathic pain with pregabalin or gabapentin at therapeutic doses in routine practice.
    Sicras-Mainar A; Rejas-Gutiérrez J; Perez-Paramo M; Navarro-Artieda R
    J Comp Eff Res; 2018 Jul; 7(7):615-625. PubMed ID: 29754518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness modeling for neuropathic pain treatments: investigating the relative importance of parameters using an open-source model.
    Hirst M; Bending MW; Baio G; Yesufu-Udechuku A; Dunlop WCN
    J Med Econ; 2018 Sep; 21(9):930-935. PubMed ID: 29882452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
    Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Páramo M; Navarro-Artieda R
    J Eval Clin Pract; 2017 Apr; 23(2):402-412. PubMed ID: 27671223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.
    Saldaña MT; Pérez C; Navarro A; Masramón X; Rejas J
    Clin Drug Investig; 2012 Jun; 32(6):401-12. PubMed ID: 22480279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature.
    Tzellos TG; Papazisis G; Amaniti E; Kouvelas D
    Eur J Clin Pharmacol; 2008 Sep; 64(9):851-8. PubMed ID: 18607580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.